Quick Answer
Corvus Pharmaceuticals, Inc. reported Stockholders Equity of $61.20 million for fiscal year 2025.
Corvus Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $61.20M | +87.9% |
| 2024 | $32.57M | -15.8% |
| 2023 | $38.68M | -31.1% |
| 2022 | $56.12M | -42.2% |
| 2021 | $97.16M | +34.7% |
| 2020 | $72.15M | +1.5% |
| 2019 | $71.11M | -35.6% |
| 2018 | $110.34M | +30.1% |
| 2017 | $84.83M | -36.1% |
| 2016 | $132.80M | +527.0% |
| 2015 | -$31.10M | -19460.4% |
| 2014 | -$159.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $71.77M | +478.4% | -10.5% |
| June 30, 2025 | $80.23M | +56.6% | +62.7% |
| March 31, 2025 | $49.33M | +47.8% | +51.5% |
| December 31, 2024 | $32.57M | -15.8% | +162.5% |
| September 30, 2024 | $12.41M | -72.0% | -75.8% |
| June 30, 2024 | $51.23M | +3.5% | +53.5% |
| March 31, 2024 | $33.36M | -31.7% | -13.8% |
| December 31, 2023 | $38.68M | -31.1% | -12.7% |
- Corvus Pharmaceuticals, Inc. showed an increase of +87.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, Corvus Pharmaceuticals, Inc.’s stockholders equity has grown by 38593.7% (from -$159.0 thousand to $61.20 million).
- The most recent figure is from Corvus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: